Alexey Kadet
Chief Business Officer Crownlands
Seminars
Wednesday 29th April 2026
What is the Direction of New Targets? Different Target Identification Strategies
1:30 pm
- Reviewing the state of play of target identification and validation, and business rationale to explore newly discovered targets
- Leveraging human genetic data to understand the efficacy of new drugs
- Discussing the optimal moment for a biotech to partner a novel target identified through an innovative platform and whether the current deal-making landscape is favouring first-in-class or best-in-class
Wednesday 29th April 2026
Showcase Your Science: Pipeline Innovation Partner Presentations
10:00 am
10.00 – EQL-988: Expanding Rapid Treatment for Suicidality Beyond Ketamine by EQUULUS Therapeutics
10.15 – Building a Best-in-class Cell Therapy for Parkinson’s Disease by Treefrog Therapeutics
10.30 – First-In-Class Inhibitors of ALOX15 for Agitation in Dementia and Pain by Kinoxis Therapeutics
10.45 – A First-in-Class Intranasal Nanobody for Treatment-Resistant Depression by EvoDenovo
11.00 – Olfactory Neurons as a Longitudinal, Molecular Window into Patient Brain Biology by Crownlands
11.15 – MB-204: A Novel A2a Receptor Antagonist to the Restore Social Reward Signal in Autism, Depression & Alzheimer’s Disease by Marvel Biotechnology
11.30 – Presentation by Beacon Neuroscience
